{
    "doi": "https://doi.org/10.1182/blood.V106.11.774.774",
    "article_title": "Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients. ",
    "article_date": "November 16, 2005",
    "session_type": "Oral Sessions",
    "abstract_text": "Background and objective. Rituximab and CHOP (R-CHOP) is the most employed treatment for DLBCL, but pts with AIDS-related lymphomas are usually excluded from clinical trials. The objective of this open, prospective multicenter trial is to evaluate the feasibility, efficacy and toxicity R-CHOP and HAART in AIDS-related DLBCL. Patients and methods. Between April 2001 and July 2005, 60 consecutive HIV-infected pts with newly diagnosed DLBCL were included in 20 Spanish hospitals. HAART was given to all patients from diagnosis if they were not already receiving it. Six cycles of R-CHOP were administered, IT CNS prophylaxis (MTX, ARA-C and hydrocortisone) was given in every cycle to all patients. G-CSF support was recommended Response to chemotherapy, toxicity, OS and DFS for complete responders were recorded. Results. Median age 42 yr (range 26\u201364), 49 (82%) males, 30 (50%) with previous known diagnosis of HIV infection (median from dx HIV to NHL 10 yr, range 0.5\u201319). Median CD4 lymphocyte count 152/mL (range 0\u2013905), median HIV load 19x10 3 copies/mL (range 0\u20132x10 6 ). 36 pts were receiving HAART at the time of NHL dx (median 3.5 yr, range 0.5\u20139). Extranodal involvement 43 (72%), stage III-IV 38 (63%) and 36/56 had intermediate-high or high age-adjusted IPI score. 10 patients are under treatment, 1 (2%) withdrawal, 6 (12%) induction death (infection 3, hepatic failure 2, multiorgan failure 1), 10 (20%) resistant, CR 33 (66%). After a median follow-up of 2 yr, 2-yr survival probability was 63% (95%CI 50\u201376). The probability of remaining alive and in first CR at 2 yr for complete responders was 89% (95%CI 77\u2013100). Three patients died in first CR (opportunistic infection, sudden death and violent death) and no relapses have occurred to date. Virologic and immunologic responses to HAART at 6 months after the completion of treatment were maintained or achieved in 17/21 (81%) and 14/22 (64%) of patients, respectively. Out of 245 R-CHOP cycles analysed the most frequent grade II-IV toxicities were infections (30, 12%), gastrointestinal (21, 9%) and neurologic (5, 2%). Conclusion. In patients with AIDS-related DLBCL the combination of HAART and R-CHOP is feasible and effective. In this trial the response rate and survival are comparable to those obtained in immunocompetent patients treated with R-CHOP.",
    "topics": [
        "acquired immunodeficiency syndrome",
        "antiretroviral therapy, highly active",
        "diffuse large b-cell lymphoma",
        "r-chop",
        "brachial plexus neuritis",
        "hiv infections",
        "infections",
        "toxic effect",
        "central nervous system prophylaxis",
        "cyclophosphamide, doxorubicin, prednisone, and vincristine"
    ],
    "author_names": [
        "Josep-Mari\u0301a Ribera, PhD",
        "Albert Oriol, MD",
        "Mireia Morgades, MD",
        "Eva Gonza\u0301lez-Barca, MD",
        "Pilar Miralles, MD",
        "Armando Lopez-Guillermo, MD",
        "Andres Lopez, MD",
        "Blanca Xicoy, MD",
        "Eugenia Abella, MD",
        "Santiago Gardella, MD",
        "Marta Garci\u0301a, MD",
        "Joan Bargay, MD",
        "Katy Perez-Equiza, MD",
        "Javier Briones, MD",
        "Lluis Rodriguez, MD",
        "Mariano Provencio, MD",
        "Lourdes Escoda, MD",
        "Alfons Soler, MD",
        "Miguel Canales, MD",
        "Antonio Asensio, MD",
        "Antonio Romero, MD",
        "Secundino Ferrer, MD",
        "Evarist Feliu, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Josep-Mari\u0301a Ribera, PhD",
            "author_affiliations": [
                "Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Badalona, Spain"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Albert Oriol, MD",
            "author_affiliations": [
                "Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Badalona, Spain"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mireia Morgades, MD",
            "author_affiliations": [
                "Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Badalona, Spain"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Eva Gonza\u0301lez-Barca, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pilar Miralles, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Armando Lopez-Guillermo, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andres Lopez, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Blanca Xicoy, MD",
            "author_affiliations": [
                "Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Badalona, Spain"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Eugenia Abella, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Santiago Gardella, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marta Garci\u0301a, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Joan Bargay, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Katy Perez-Equiza, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Javier Briones, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lluis Rodriguez, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mariano Provencio, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lourdes Escoda, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alfons Soler, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Miguel Canales, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonio Asensio, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonio Romero, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Secundino Ferrer, MD",
            "author_affiliations": [
                "Hematology, PETHEMA, GELTAMO, GESIDA and GELCAB Groups, Barcelona, Spain"
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Evarist Feliu, MD",
            "author_affiliations": [
                "Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Badalona, Spain"
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-04-28T18:37:44",
    "is_scraped": "1"
}